| 1.14 0.01 (0.89%) | 10-08 13:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.39 |
1-year : | 1.62 |
| Resists | First : | 1.19 |
Second : | 1.39 |
| Pivot price | 1.11 |
|||
| Supports | First : | 1.12 |
Second : | 1.08 |
| MAs | MA(5) : | 1.11 |
MA(20) : | 1.11 |
| MA(100) : | 1.3  |
MA(250) : | 1.85 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.9 |
D(3) : | 24.8 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 4.59 | Low : | 1.08 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RLYB ] has closed below upper band by 14.8%. Bollinger Bands are 68.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.14 - 1.15 | 1.15 - 1.15 |
| Low: | 1.1 - 1.1 | 1.1 - 1.11 |
| Close: | 1.12 - 1.13 | 1.13 - 1.14 |
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Tue, 01 Oct 2024
Rallybio shares hold Buy rating on HPP treatment data - Investing.com
Mon, 30 Sep 2024
Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com
Wed, 28 Aug 2024
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully - Simply Wall St
Tue, 27 Aug 2024
Rallybio to Present at Upcoming Investor Conferences - Business Wire
Wed, 14 Aug 2024
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 1.961e+007 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 623 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.386e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 697.3 % |
| Return on Equity (ttm) | -38.6 % |
| Qtrly Rev. Growth | 299000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.86 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.01 |
| Dividend | 0 |
| Forward Dividend | 579070 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|